Zoetis Inc. has received marketing authorization from the European Commission for Portela® (relfovetmab), a new monoclonal antibody therapy for alleviating pain associated with osteoarthritis in cats. Portela is the first monoclonal antibody treatment with a three-month dosing interval approved for this use in cats, providing a long-acting solution that targets nerve growth factor (NGF), a key mediator of osteoarthritis pain and inflammation. The approval was based on positive safety and efficacy data, including a nine-month field trial in Europe. Zoetis plans to make Portela commercially available in the European Union in 2026. No other organizations were mentioned as recipients of this regulatory approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251028797286) on October 29, 2025, and is solely responsible for the information contained therein.